RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $29
RBC Capital analyst Gregory Renza maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $30 to $29.
ADC Therapeutics Q2 EPS $(0.73) Beats $(0.91) Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 4.29 percent decrease over losses of $(0.70) per share from the
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Why ADC Therapeutics Shares Are Rising Today
ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the development and commercialization of ZYNLONTA.
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
ADC Therapeutics SA (NYSE:ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC:BIOVF) for the development and commercialization of…
ADC Therapeutics Announced Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA in Europe and Select International Territories; ADC Therapeutics is Eligible to Receive Up to $435M, Including Milestones
ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301)…
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: